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Background Chronic HCV infection is a leading cause
of liver-related morbidity globally. The innate and
adaptive immune responses are thought to be important
in determining viral outcomes. Polymorphisms associated
with the IFNL3 (IL28B) gene are strongly associated with
spontaneous clearance and treatment outcomes.
Objective This study investigates the importance of
HLA genes in the context of genetic variation associated
with the innate immune genes IFNL3 and KIR2DS3.
Design We assess the collective inﬂuence of HLA and
innate immune genes on viral outcomes in an Irish
cohort of women (n=319) who had been infected from
a single source as well as a more heterogeneous cohort
(Swiss Cohort, n=461). In the Irish cohort, a number of
HLA alleles are associated with different outcomes, and
the impact of IFNL3-linked polymorphisms is profound.
Results Logistic regression was performed on data
from the Irish cohort, and indicates that the HLA-A*03
(OR 0.36 (0.15 to 0.89), p=0.027) -B*27 (OR 0.12
(0.03 to 0.45), p=<0.001), -DRB1*01:01 (OR 0.2 (0.07
to 0.61), p=0.005), -DRB1*04:01 (OR 0.31 (0.12 to
0.85, p=0.02) and the CC IFNL3 rs12979860 genotypes
(OR 0.1 (0.04 to 0.23), p<0.001) are signiﬁcantly
associated with viral clearance. Furthermore,
DQB1*02:01 (OR 4.2 (2.04 to 8.66), p=0.008),
KIR2DS3 (OR 4.36 (1.62 to 11.74), p=0.004) and the
rs12979860 IFNL3 ‘T’ allele are associated with chronic
infection. This study ﬁnds no interactive effect between
IFNL3 and these Class I and II alleles in relation to viral
clearance. There is a clear additive effect, however. Data
from the Swiss cohort also conﬁrms independent and
additive effects of HLA Class I, II and IFNL3 genes in
their prediction of viral outcome.
Conclusions This data supports a critical role for the
adaptive immune response in the control of HCV in
concert with the innate immune response.
INTRODUCTION
Infection with HCV is one of the leading causes of
liver-related mortality globally. Most persons who
are exposed to HCV will develop persistent infec-
tion; however, a proportion (20–30%) spontan-
eously clear infection. Those patients with chronic
HCV infection are at risk of developing liver cir-
rhosis and/or hepatocellular carcinoma.1 Much
effort has aready been invested in understanding
the factors that determine the differing outcomes in
individuals but disentangling the impact of host
and viral factors has been difﬁcult. One of the
reasons for this is that HCV exhibits substantial
genetic heterogeneity as a consequence of its error-
prone polymerase enzyme,2 3 and high replication
rates with virion production exceeding 1012 parti-
cles per day.4
Signiﬁcance of this study
What is already known on this subject?
▸ Host factors are considered to be an important
component in the control of HCV infection.
▸ The HLA genes, as well as the innate immune
genes IFNL3 and KIR, are considered to be
important determinants of viral outcomes,
however, their interaction with each other has
not been well studied.
▸ A single source outbreak of HCV provides us
with a unique opportunity to understand the
nature of these genetic inﬂuences in more
detail as confounding factors are controlled.
What are the new ﬁndings?
▸ HLA Class I and II genes are signiﬁcantly
associated with viral outcomes even when the
profound impact of IFNL3 and KIR2DS3 are
considered.
▸ There is no evidence of a genetic interaction
effect between the HLA Class I and II alleles
and IFNL3.
▸ There is, however, a clear additive effect
between the different genes indicating likely
independent and separate but cumulative
immune events.
▸ The results also indicate that there may be a
differential effect with respect to HLA Class I
alleles and viral outcomes according to the
nature of the innate immune response.
▸ These data support a critical role for the
adaptive immune response alongside the innate
immune response in the control of HCV
infection.
How might it impact on clinical practice in
the foreseeable future?
▸ These data provide important insights to the
immunopathogenesis of this illness which is of
direct relevance to HCV vaccine studies and
design.
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Nonetheless, there are clear reports of host factors that are
inﬂuential in determining viral outcome. The cellular immune
response coordinated by CD4 and CD8 T cells appears to be
important in this process. These responses are genetically prede-
termined by the nature of the host’s major histocompatibility
complex (MHC) molecules which dictate the antigen recognised
in each individual. Certain HLA Class I and II genes have been
linked to differing viral outcomes. Of the Class I genes,
HLA-A*03, -B*27, -B*57 and C*01 have been shown to associ-
ate signiﬁcantly with viral clearance.5 6 Similarly, the Class II
alleles have also been implicated—HLA-DRB1*01:01, 04:01
and DQB1*03:01 are associated with viral clearance, while
others, such as DQB1*02:01 and DRB1*03:01, are associated
with persistence.5 7 Functional studies have linked the Class I
associations (in the case of -A*03 and -B*27) to targeting of key
protective CD8 T cell epitopes which appear to have a high
ﬁtness cost requiring the generation of multiple mutations.8 9
The mechanism underpinning the protection associated with
HLA Class II is not yet fully understood.
The innate immune response also appears to be crucial to
viral containment. The interferon lambda 3 (IFNL3) gene
encodes an innate interferon—IFN lambda 3 (IFNλ3) and a
body of evidence supports a critical role for this cytokine in
HCV infection. IFNλ3 is classiﬁed as a type III interferon.
These cytokines possess antiviral and immunomodulatory
activity mediated through the JAK-STAT pathway and can
upregulate expression of interferon-stimulated genes (ISG).10
The importance of variants linked to this gene was ﬁrst iden-
tiﬁed in a genome wide association study (GWAS) when a
group of single nucleotide polymorphisms (SNP) identiﬁed at
speciﬁc sites within a haplotype block were found to strongly
correlate with either persistence or clearance of HCV in
patients receiving interferon treatment.11 The exact mechan-
ism responsible for this strong IFNL3 effect remains unclear.
However, despite the strong IFNL3 effect, outcome is pre-
dicted in only about two-thirds of cases.10
As previously mentioned, much effort has been invested in
determining the crucial host factors that help determine how
HCV is controlled in humans. A number of important insights
to this have arisen from the study of a cohort of Irish women
who were accidentally exposed to HCV after receipt of doses of
infected anti-D immunoglobulin.12 This cohort is deﬁned by
exposure to the same strain (genotype 1b) at a deﬁned time
point. The single-source outbreak of HCV infection presents an
ideal study group in which to address the impact of host and
viral factors, as host and viral heterogeneity are controlled for.
The characteristics of this cohort have allowed several observa-
tions to be described, which have not been so clear-cut in other
groups. Genetic studies have identiﬁed clear HLA Class I asso-
ciations (table 1). A*03, B*27 and C*01 are associated with
viral clearance whilst HLA-B*57 is not.5 Similarly, clear associa-
tions between HLA Class II genes and outcomes have been
observed. HLA-DRB1*01:01, *04:01 and DRB1*15 have been
linked to viral clearance, while DQB1*02:01 was associated
with chronic infection.5 18 Two recent studies also provide
powerful evidence of the importance of IFNL3 in determining
outcomes in this group.16 17 Dring et al have studied the impact
of the rs12979860 IFNL3-linked polymorphism in more than
500 women derived from this cohort. They found the presence
of the ‘T’ allele strongly predicted chronic infection (OR 7.38,
p<10−8). They also found that the KIR2DS3 gene in combin-
ation with the HLA-C2 (an epitope of HLA-C molecules that
provides a ligand for some NK cell receptors) also predicted
viral persistence (OR 1.90, p<0.002).16 Previous studies have
also identiﬁed an effect of KIR genes on viral outcomes in HCV
infection although not speciﬁcally KIR2DS3.19–21
In this study, we aimed to address a question, which has not
previously been reported upon—to deﬁne the impact of
genetic variation in innate immune genes (IFNL3 and
KIR2DS3) on the protective nature of MHC Class I and II, and
were in a unique position to study this in the Irish cohort of
women infected with a common inoculum of HCV from
anti-D injections. We hypothesised that in patients who have a
suboptimal innate immune response, a favourable adaptive
immune response, such as that associated with protective HLA
Class I and II alleles, might have a differential effect on viral
outcomes or vice versa. As innate interferons may very well
have an effect on the quality of the subsequent adaptive
immune response, we also address whether IFNL3 and the
HLA Class I and II genes have separate, additive or interactive
effects on HCV clearance.
METHODS
Cohort
The study population is a group of Irish women who were
exposed to HCV (genotype-1b) as a consequence of receipt of
contaminated anti-D immunoglobulin in 1977. The character-
istics of this cohort have been previously published.12 The sub-
jects in this study were attending different centres in Ireland.
Informed and written consent was obtained from each partici-
pant and ethical approval was obtained previously from the
local centres. Our study group is comprised of 319 patients
derived from the cohort (table 2) Complete HLA Class I, II,
KIR2DS3 and IFNL3 genotyping was not available on all
patients. In Group 1 (n=319), we had access to complete HLA
Class I, KIR2DS3 and IFNL3 rs12979860 genotyping. Group 2
(n=213) is a subset of the ﬁrst group: however, in this case, we
also have full Class II typing.
Data was also available from 461 patients derived from the
Swiss HIV Cohort Study (previously described, and also in
(http://www.shcs.ch).17 This is a multiple source cohort com-
posed of HIV/HCV coinfected individuals (208 spontaneous
clearers and 253 with chronic infection). These patients were
infected with diverse HCV genotypes and were heterogeneous
with respect to age, sex, ethnicity and viral co-infections (see
online supplementary table S1). Data was available on HLA
Class I, II and IFNL3 rs4803217 genotypes. Written informed
consent including for genetic testing had previously been
obtained.
Table 1 Genes previously associated with favourable and
unfavourable outcomes within the Irish cohort
Protective Deleterious OR (95% CI) References
HLA-B*27 7.99 (1.90 to 33.51) 5
HLA-A*03 2.43 (1.2 to 4.85) 5
HLA-C*04 — 13
HLA-DRB1*01:01 4.71 (2.11 to 10.49) 5, 14, 15
DRB1*04:01 4.12 (2.04 to 8.34) 5
DRB1*15 2.2 (1.21 to 3.99) 5
DQB1*02:01 0.27 (0.14 to 0.52) 5
KIR2DS3 2.27 (1.28 to 4.02) 16
IL28B ‘T’ 7.59 (4.86 to 11.8) 16, 17
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IFNL3, KIR2DS3 and HLA genotyping
Genotyping for these variables (IFNL3 SNP rs12979860,
KIR2DS3 and HLA) in the Irish cohort was performed previ-
ously and is described in previous publications.5 16 18 For the
Swiss cohort, genotyping for the IFNL3 linked polymorphism
rs4803217 was performed. This SNP was chosen as a proxy (R2
of 0.92) for rs12979860 because the latter SNP was not geno-
typed in the frame of the Swiss cohort GWAS. HLA type was
imputed using the SNP2HLA pipeline and a reference panel of
5225 individuals with MHC-wide dense SNP typing and 4-digit
sequence-based HLA typing.22
Statistical analysis
For the Irish data, Fisher’s exact test and step-wise multivariate
logistic regression analysis is used to assess the predictive contri-
bution of HLA type in a model that also includes the patient’s
IFNL3 status and KIR2DS3 genotype. Stepwise logistic regres-
sion models were produced using forward and backward vari-
able selection. The R step function was used to minimise Akaike
Information Criteria (AIC). The additive effect of the selected
HLA type, IFNL3 and KIR2DS3 was examined by hierarchical
modelling and receiver operator curves (ROC). The interaction
of IFNL3 and the optimised HLA types was assessed within the
regression models. For the Swiss data, univariate regression was
performed for outcome for each HLA (see online supplemen-
tary data). The rest of the analysis follows the same procedures
as the analysis for the Irish cohort. All analysis is carried out
using R (http://www.r-project.org) V.3.10.
RESULTS
HLA Class I alleles are associated with viral clearance
In this study, complete HLA Class I data was available on 319
patients derived from the Irish anti-D cohort (Group 1). A pre-
vious study has reported signiﬁcant associations between Class I
alleles and viral outcomes on a smaller subset of this cohort
(n=247, table 1).5 We initially compared the frequencies of the
Class I alleles in patients with chronic and resolved infection in
these 319 patients. Our results also indicate a favourable associ-
ation between HLA-A*03 (OR 0.5 (0.3 to 0.9), p=0.01) and
B*27 (OR 0.3 (0.1 to 0.9), p=0.02) and viral clearance.
Additionally, C*01 (OR 0.3 (0.08 to 1), p=0.03), C*12 (OR
0.4 (0.1 to 1), p=0.03) and B*15 (OR 0.3 (0.1 to 1), p=0.04)
are signiﬁcantly associated with viral clearance, while C*04 (OR
2 (1 to 4), p=0.04) is associated with persistent infection.
HLA-A*03 is signiﬁcantly protective only in the IFNL3
‘protective’ group, while B*27 and C*01 are protective
only in the IFNL3 ‘deleterious’ group
To address the effect of the IFNL3 SNP rs12979860 on the
HLA Class I associations, we then stratiﬁed the cohort according
to carriage of the ‘protective’ CC genotype or ‘deleterious’ T+
genotype and re-analysed viral outcomes in these groups (table 3
and see online supplementary table S3 and S4). In those with the
protective IFNL3 genotype, HLA-A*03 is still strongly associated
with viral clearance (OR 0.34 (0.14 to 0.8), p=0.007). The pres-
ence of HLA-A*03 is also more common in resolvers than in
those with persistent infection in the deleterious IFNL3 group
(35% vs 25%, OR 0.6 (0.2 to 1.7), p=0.35) although this is no
longer statistically signiﬁcant. In the group stratiﬁed by the
IFNL3 ‘deleterious’ genotype, we identify signiﬁcant associations
between HLA-B*27, -C*01 and viral clearance (OR 0.12 (0.02 to
0.6), p=0.002 and OR 0.11 (0.02 to 0.6), p=0.005, respectively)
and observe that this effect is not present in the ‘protective’
group (table 3). The number of patients who have these import-
ant alleles (B*27, C*01) is low, however.
Table 2 The Irish cohort has been divided into two study groups
according to the availability of genotyping
IFNL3 T+ IFNL3 CC HLA Class I HLA Class II
Group 1 n=319 163 156 319 —
SR 29 94 124 —
Chronic 134 62 196 136
Group 2 n=213 110 103 213 213
SR 21 56 77 77
Chronic 89 47 136 136
SR, spontaneous resolver.
Table 3 HLA Class I and II associations with viral outcome in patients from the Irish stratified by their IFNL3 rs12979860 genotype (Fishers
exact test)
IFNL3 rs12979860 CC genotype IFNL3 rs12979860 T+ genotype
HLA Chronic n=62 (%) Resolved n=94 (%) OR (95% CI) p Value Chronic n=134 (%) Resolved n=29 (%) OR (95% CI) p Value
A*03 10 (16) 34 (36) 0.34 (0.14 to 0.8) 0.007 33 (25) 10 (35) 0.6 (0.2 to 1.7) 0.35
B*27 4 (7) 8 (9) 0.7 (0.2 to 3) 0.77 4 (3) 6 (21) 0.12 (0.02 to 0.6) 0.002
C*01 2 (3) 5 (5) 0.6 (0.06 to 3.8) 0.7 3 (2) 5 (17) 0.11 (0.02 to 0.6) 0.005
B*15 3 (5) 7 (7) 0.6 (0.1 to 3) 0.74 3 (2) 4 (14) 0.2 (0.02 to 0.9) 0.02
Cw*16 11 (18) 6 (6) 3.1 (1 to 11) 0.035 7 (5) 7 (24) 0.3 (0.07 to 1.2) 0.04
C*09 5 (8) 1 (1) 8.1 (0.9 to 389) 0.037 4 (3) 1 (3) 0.9 (0.08 to 44) 1
HLA Chronic n=47 Resolved n=56 OR (95% CI) p Chronic n=89 Resolved n=21 OR (95% CI) p
DRB1*01:01 3 (5) 17 (18) 0.16 (0.03 to 0.6) 0.002 8 (6) 9 (31) 0.14 (0.04 to 0.5) 0.001
DQB1*05:01 8 (13) 20 (21) 0.4 (0.1 to 1) 0.045 11 (8) 9 (31) 0.2 (0.06 to 0.6) 0.003
DQB1*02:01 18 (29) 9 (10) 3.2 (1.2 to 9.3) 0.014 38 (28) 2 (7) 7 (1.5 to 66) 0.005
DRB1*03:01 17 (27) 9 (10) 2.9 (1.1 to 8.5) 0.024 38 (28) 2 (7) 7 (1.5 to 66) 0.005
DRB1*04:01 9 (15) 17 (18) 0.5 (0.2 to 1.5) 0.26 11 (8) 5 (17) 0.5 (0.1 to 2) 0.18
DQB1*02:02 14 (23) 4 (4) 5.4 (1.5 to 25) 0.004 19 (14) 4 (14) 1.2 (0.3 to 5.3) 1
DR*13:01 9 0 0 0 11 2 1.3 (0.3 to 13.4)
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HLA Class II data was available for 213 women (Group 2).
Online supplementary table S5 shows the frequencies of the
Class II alleles in patients with different outcomes in this ana-
lysis and are similar to previous studies.5 15 18 We also stratiﬁed
the group according to the presence or absence of the beneﬁcial
IFNL3 genotype. HLA-DQB1*02:01 and DRB1*03:01 were
both signiﬁcantly associated with chronic infection independ-
ently of the stratiﬁcation. Similarly, DQB1*05:01 and
DRB1*01:01 were both signiﬁcantly enriched in those with
viral clearance irrespective of the IFNL3 genotype (table 3 and
see online supplementary tables S6 and S7). These results
suggest an independent effect of the Class II genes as a contribu-
tor to viral outcome.
HLA Class I alleles predict viral outcome even when
the impact of innate immune genes are considered
Logistic regression analysis was then used to generate an
optimal multivariate model that would best predict viral
outcome using the previously identiﬁed associations and genes
noted to be in linkage disequilibrium. The IFNL3 and KIR2DS3
genotype were also incorporated. Table 4 presents the optimised
regression model of class I HLA, KIR2DS3 and IFNL3 associa-
tions with viral clearance. Four of the HLAs are protective
(A*03, B*15, C*01 and C*12) whilst C*09 is deleterious.
These associations are maintained independently despite the
presence of IFNL3 within the regression even though IFNL3
has a strong protective effect (OR 0.11, (0.06 to 0.19),
p<0.001). The interactive effect of the IFNL3-associated poly-
morphisms with the Class I alleles was examined by including
interaction terms in the logistic regression models. No signiﬁ-
cant interactions were detected. The additive effects were
assessed by constructing hierarchical models. Models were con-
structed using only the optimal HLA I alleles or KIR2DS3 or the
IFNL3 genotype and combinations of these predictors. As vari-
ables are added, there is a marked improvement in prediction of
viral clearance. Online supplementary ﬁgure S2. displays the
ROC generated by these models. The best model as deﬁned
by area under the curve (AUC 0.82) contains all the predictors.
The IFNL3 genotype (AUC 0.72) outperforms KIR (AUC 0.59)
and HLA Class I alleles (AUC 0.65) when considered on
their own.
Predictive effect of immune genes are additive
We next generated a logistic regression model to predict viral
outcome incorporating Class I and Class II alleles as well as
IFNL3 and KIR2DS3 genotype. The regression included genes
that were known to be enriched in patients with viral clearance
or chronic infection, also genes noted to be in linkage disequi-
librium with the former, in addition to the IFNL3 and KIR2DS3
genotype. HLA-A*03 (OR 0.36 (0.15 to 0.89), p=0.027),
-B*27 (OR 0.12 (0.03 to 0.45), p=<0.001), IFNL3 CC geno-
type (OR 0.1 (0.04 to 0.23), p<0.001), DRB1*01:01 (OR 0.2
(0.07 to 0.61), p=0.005), and DRB*04:01 (OR 0.31 (0.12 to
0.85, p=0.02) were signiﬁcantly associated with viral clearance
(table 5). DRB*13:01 (OR 5.95 (0.97 to 36.7), p=0.05),
DQB1*02:01 (OR 4.2 (2.04 to 8.66), p=0.008), as well as the
IFNL3 ‘T’ allele and KIR2DS3 (OR 4.36 (1.62 to 11.74),
p=0.004) genotype were found to be associated with chronic
infection (table 5.)
As previously, we generated a model (ROC) to predict viral
outcome incorporating the genes identiﬁed above (see online
supplementary ﬁgure S3). This again demonstrates an additive
effect of the variables. HLA Class I and II genes combined are
able to predict viral outcome (AUC 0.82) better than either
KIR2DS3 (AUC 0.61) or IFNL3 (AUC 0.69) alone. There is an
improvement in prediction with the addition of all variables.
The curve also demonstrates that the combined predictive HLA
genes offer a good prediction of outcome (AUC 0.82) with only
a slight improvement with the addition of IFNL3 gene status
and KIR2DS3 (AUC 0.89).
Additive effects of HLA and IFNL3 genes are also present in
an independent Swiss cohort
Given the unique characteristics of the Irish cohort as a group,
we set out to address whether our observations in this dataset
were reproducible in an independent heterogeneous population.
HLA Class I and II as well as IFNL3 genotypes (using the
rs12979860 proxy SNP rs4803217, proxy R2=0.92) were avail-
able on 461 members of the Swiss cohort. The frequencies of
the different HLA alleles in the Irish and Swiss cohorts are
shown in online supplementary ﬁgures S4–S8. We again gener-
ated an optimised logistic regression model using the Swiss
cohort genetic data to predict viral outcome (table 6). The
strongest HLA predictor is HLA-A*11 which signiﬁcantly pre-
dicts viral persistence in the Swiss cohort (p=0.004, OR 2.63
(CI 1.35 to 5.1). In the Irish cohort, there is also a trend
towards an association between chronic infection and
HLA-A*11 albeit not signiﬁcant. Other studies have also
Table 4 An optimised logistic regression model (incorporating
HLA Class I, IFNL3 and KIR) predicting viral clearance
Explanatory Variables OR (95% CIs) p Value
A*03 0.42 (0.23 to 0.76) 0.005
B*15 0.12 (0.03 to 0.52) 0.004
C*01 0.13 (0.03 to 0.5) 0.003
C*09 10.74 (1.42 to 81.3) 0.022
C*12 0.31 (0.11 to 0.86) 0.024
IFNL3 CC versus CT/TT 0.11 (0.06 to 0.19) <0.001
KIR2DS3 3.45 (1.77 to 6.72) <0.001
The explanatory variables are selected by forward and reverse stepwise selection
minimising Akaike Information Criteria. OR, CIs and p values are presented. The
dataset consists of patients from the Irish cohort who have had their HLA Class I
genotype determined (n=319).
IFNL3 CC, protective genotype; IFNL3 CT/TT, deleterious genotype.
Table 5 An optimised logistic regression model (incorporating
HLA Class I and II, IFNL3 and KIR) predicting viral clearance
Explanatory variables OR and confidence limits p Value
A*02 2.32 (0.95 to 5.66) 0.064
A*03 0.36 (0.15 to 0.89) 0.027
A*11 2.36 (0.76 to 7.33) 0.137
B*07 0.49 (0.2 to 1.21) 0.122
B*27 0.12 (0.03 to 0.45) <0.001
C*02 32.38 (1.62 to 645) 0.023
DR*04:01 0.31 (0.12 to 0.85) 0.022
DR*01:01 0.2 (0.07 to 0.61) 0.005
DR*13:01 5.95 (0.97 to 36.67) 0.054
DQ*02:01 4.2 (2.04 to 8.66) 0.008
IFNL3 CC v CT/TT 0.1 (0.04 to 0.23) <0.001
KIR2DS3 4.36 (1.62, 11.74) 0.004
The explanatory variables are selected with stepwise selection minimising Akaike
Information Criteria (AIC). OR, CIs and p values are presented. The dataset consists of
patients from the Irish cohort (n=213).
IFNL3 CC: protective genotype; IFNL3 CT/TT: deleterious genotype.
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suggested a predictive role for A*11 in other populations.23 The
-DQB1*0301 allele is signiﬁcantly associated with viral clear-
ance (p=0.032, OR 0.66 (0.45 to 0.97)) as is the protective
IFNL3-associated rs4803217-C allele.
A ROC was generated to address the combined impact of the
HLA alleles and IFNL3 genotypes on viral outcomes in this
cohort (see online supplementary ﬁgure S9). Similar to the
results observed in the Irish cohort, we note an additive effect
in the prediction of viral outcome between HLA alleles and
IFNL3 genotypes. This effect is less marked than that of the
Irish cohort (0.65 AUC IFNL3 alone ct. 0.72 for HLA and
IFNL3). Nonetheless, it provides evidence that innate and adap-
tive immune events are independent and additive in the predic-
tion of viral outcomes.
DISCUSSION
In this study, we aimed to deﬁne the established associations
between MHC genes and viral outcomes in the context of the
IFNL3-linked polymorphisms. We were in a unique position to
address this, as we were able to investigate these relationships in
a cohort of women who had been infected with HCV from a
single source. We wished to address whether the observed
MHC associations would remain signiﬁcant in the context of
the profound innate immune effect.
We ﬁrst considered whether there might be a differential
effect according to the characteristics of the innate immune
response, by analysing the impact of carriage of either the pro-
tective or deleterious IFNL3 genotype with respect to the HLA
effect on viral outcomes. In our HLA Class I analysis, we did, to
an extent, observe this effect. The presence of the protective
alleles HLA-B*27 and –C*01 was signiﬁcantly enriched in those
with viral clearance if the unfavourable IFNL3 genotype was
present. In this cohort, the HLA-B*27 and C*01 alleles are
infrequent (6% of population), and so the numbers in the study
are limited. We also ﬁnd that carriage of the protective
HLA-A*03 allele was signiﬁcantly associated with clearance only
in the presence of the IFNL3 CC genotype. These results indi-
cate that there may indeed be a differential effect with respect
to HLA Class I alleles and viral outcomes, according to the
nature of the innate immune response. Larger studies would be
required to conﬁrm these observations however. In the case of
Class II alleles, the results are more clear-cut suggesting an
effect that is independent of the IFNL3 genotype as the
protective or deleterious effects of the Class II alleles were
maintained irrespective of the stratiﬁcation.
In our initial optimised multivariate model, we assessed the
impact of HLA Class I alleles on viral outcomes in a regression
incorporating the IFNL3 status and KIR2DS3 genotype. Results
from this model reveal protective roles for the Class I alleles
A*03, B*15, C*01 and C*12 and a deleterious role for C*09.
We have previously studied the protective effect of HLA-A*03
and linked its effect to presentation of an immunodominant
CD8 T cell epitope. HLA-B*15 has not previously been linked
to protection in this cohort, but these results suggest a possible
role. A large study by Hraber et al does report on an association
between B*62 (a B*15 supertype) and viral clearance24 and
functional studies also indicate the targeting of dominant CD8
T cell epitopes restricted by this allele.25 HLA-B*27 and -C*01
are inherited in strong linkage disequilibrium within this cohort.
In our initial logistic regression analysis (n=319), C*01 appears
as a signiﬁcant predictor—however, in the later model which
combines Class I and II alleles (n=213), it is the B*27 allele
which is the best predictor of viral clearance. The numbers
studied are low, however (n=22 for HLA B*27, Study group 1),
and this makes it difﬁcult to separate the effects of these closely
linked genes. In this cohort, several other haplotypes are inher-
ited in linkage disequilibrium.5 HLA-A*01-B*08-Cw*07 is linked
to the Class II haplotype DRB1*03:01-DQB1*02:01—however,
only DQB1*02:01 was noted to be a predictor of persistent
infection in this study. The HLA-A*03 allele occurred in linkage
with B*07-DRB1*15-DQB1*06:02. In this study, we ﬁnd that
only the A*03 component is predictive of viral clearance.
As well as being potential predictors in their own right as part
of the adaptive immune response, HLA class I C alleles can be
divided into two groups (C1 and C2) based on KIR ligand speci-
ﬁcity. Prior work with this and other cohorts have considered
the impact of this grouping, and found signiﬁcant associations
and interactions between viral clearance, HLA C1 or C2 and
IFNL3 genotype.16 21 Suppiah et al have previously addressed
the role of HLA-C alleles in combination with IL28B in predict-
ing treatment outcomes in HCV. They found the HLA-C2C2
genotype to be over-represented in patients who failed treat-
ment (OR 1.52), and that prediction of treatment failure
improved from 66% to 80% if both genes were used. They
noted that this effect was mainly additive, but there was some
evidence that it was also partially due to genetic interaction.21
Dring et al16 report on a signiﬁcant association between
KIR2DS3 on a HLA C2C2 background in the Irish cohort in
predicting the development of persistent infection, and also
report signiﬁcant synergy between KIR 2DS3 gene and the
unfavourable IFNL3 polymorphism in this cohort.
In this cohort, several HLA Class II genes have been ﬁrmly
implicated as determinants of viral outcome (table 2).5 Other
immunogenetic studies of HCV have identiﬁed different associa-
tions with Class II genes according to the population and geno-
type under investigation.26 Nonetheless, several HLA Class II
genes appear to be important in diverse populations. A
meta-analysis supported a strong association between
DQB1*03:01 and DRB1*11:01 and viral clearance.7 Thio
et al27 previously noted that the DRB1*03:01-DQB1*02:01
haplotype was also deleterious in Caucasian patients. In this
study, we demonstrate that the Class II alleles (DRB1*01:01 and
*04:01) retain their highly signiﬁcant protective effect, while
DQB1*02:01 retains its deleterious effect independently of
IFNL3 and KIR2DS3. Similar to our ﬁndings with the Class I
alleles, we note that the prediction of viral outcomes are
enhanced if these effects are combined, and that is not
Table 6 Optimised logistic regression model from the Swiss
cohort (incorporating HLA Class I, II and IFNL3) predicting viral
clearance
Explanatory variables OR and confidence limits p Value
A*11 2.63 (1.35 to 5.1) 0.004
A*23 3.14 (1.05 to 9.38) 0.041
A*29 1.92 (0.087 to 4.23) 0.096
B*08 0.62 (0.35 to 1.1) 0.1
B*49 0.44 (0.21 to 0.94) 0.034
C*14 0.37 (0.14 to 0.95) 0.033
DR*08:01 0.54 (0.24 to 1.19) 0.127
DQ*03:01 0.66 (0.45 to 0.97) 0.032
DQ*03:02 1.69 (0.97 to 2.96) 0.061
rs4803217-A (IFNL3) 2.43 (1.72 to 3.43) <0.001
Explanatory variables are selected with stepwise selection minimising AIC. ORs, CIs
and p values are presented.
The dataset consists of patients from the Swiss cohort (n=461).
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accounted for by a genetic interaction. These results support
other recently published data. Duggal et al reported on a large
GWAS of spontaneous resolution of HCV. This study combines
data from different cohorts with 2401 persons included in the
ﬁnal analysis.28 Signiﬁcant differences in allele frequencies
between persons with spontaneous resolution and persistence
were identiﬁed on chromosomes 19 and 6. On chromosome 19,
the differences localised near IFNL3 while on chromosome 6,
differences localised near genes for HLA Class II and included a
polymorphism near DQB1*03:01. In the Swiss cohort, we also
noted a strong protective effect for this allele, and many other
studies have observed this effect.27–29 The associations observed
on chromosome 19 and 6 were noted to be independent and
additive. In a smaller study, Mangia et al have assessed the
impact of several protective Class II alleles on spontaneous viral
outcomes in the context of the IFNL3 SNP rs1297860 in a
small cohort of thalassemic HCV-exposed patients. They have
also demonstrated an independent and signiﬁcant effect for the
HLA Class II gene DQB1*03:01 in predicting viral clearance,
and have shown that the effects of DQB1*03:01 and IFNL3 are
additive.30 In our study, and as previously reported,
DQB1*03:01 was not found to be associated with viral out-
comes. In the Irish population, DRB1*01:01 and DQB1*02:01
are strongly associated with clearance and chronic infection,
respectively. The Class II allele DRB1*0401 is associated with
clearance in the Irish cohort, while in the Swiss Cohort it is asso-
ciated with persistence. These disparate results likely reﬂect the
frequencies of different alleles within differing populations, and
are likely to relate to the unique inoculum received by the Irish
women and the related immune speciﬁcities. In this study, we
note that the magnitude of prediction for the combined HLA I
and II genetic data (AUC 0.82) is stronger than IFNL3 alone
(AUC 0.69) or KIR2DS3 (0.61), which supports a critical role for
the adaptive immune response in determining viral outcome.
A key question which arises when we study genetic factors in
this unique population infected from a single source, is how do
our ﬁndings extrapolate to more genetically heterogeneous
populations infected with different genotypes. To address this,
we were able to compare our ﬁndings with those from a separ-
ate European population. We demonstrate that HLA Class I and
II alleles as well as IFNL3 genes independently contribute to
viral outcomes also. Furthermore, as we noted in our initial
studies, we ﬁnd that combining these different genotypes is
additive in the prediction of viral outcome. This effect is less
marked than noted in the Irish population, however, this is not
a surprising result given the unique genetic and virological
characteristics of this speciﬁc cohort. We observe different HLA
associations in these cohorts which is most likely related to viral
diversity (single strain vs diverse genotypes). Previous work on
the Irish cohort has already illustrated the unique effects of a
single infecting strain on viral evolution and immunodomi-
nance. In the Irish cohort, HLA-A*03 and -B*27 have been
shown to mediate their protective effects through presentation
of key immunodominant epitopes which have a high threshold
to the development of immune escape variants. When these epi-
topes were examined in other diverse populations, these proper-
ties were not maintained.31 32 The importance and inﬂuence of
the source virus is illustrated in a study which investigated the
roles of HLA-A*03, B*08 and B*27 in determining viral
outcome in the East German single-source outbreak. By contrast
with the Irish cohort, these alleles were neutral for disease
outcome. Sequence analysis of the immunodominant epitopes
revealed that pre-existing substitutions in the infection source of
both cohorts inﬂuenced the impact of the corresponding
HLA-allele. The epitopes presented by the ‘protective’ alleles
HLA-A*03 and -B*27 in the Irish cohort contained substitutions
in the source virus of the East German outbreak. These pre-
existing substitutions altered selection pressure and viral evolu-
tion in the East German cohort.33
In conclusion, our results conﬁrm the ﬁnding that HLA alleles
are important predictors of viral response even given the power-
ful effect of IFNL3-linked polymorphisms. The observations
demonstrated in the initial Irish studies have been reproducible
in the Swiss cohort providing corroborative evidence that adap-
tive and innate immune events independently contribute to viral
outcome, and that these events are additive.
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